| Autor: |
Olsson KM; Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Hannover, Germany olsson.karen@mh-hannover.de.; Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center of Lung Research (DZL), Hannover, Germany., Fuge J; Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Hannover, Germany.; Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center of Lung Research (DZL), Hannover, Germany., Park DH; Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Hannover, Germany.; Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center of Lung Research (DZL), Hannover, Germany., Kamp JC; Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Hannover, Germany.; Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center of Lung Research (DZL), Hannover, Germany., Berliner D; Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany., von Kaisenberg C; Department of Obstetrics, Gynaecology and Reproductive Medicine, Hannover Medical School, Hannover, Germany., Hoeper MM; Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Hannover, Germany.; Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center of Lung Research (DZL), Hannover, Germany. |
| Abstrakt: |
Competing Interests: Conflict of interest: K.M. Olsson has received fees for lectures or consultations from Acceleron, Actelion, Bayer, Ferrer, Janssen and MSD, all unrelated to the present work. J. Fuge has received fees for consultations from AstraZeneca unrelated to the submitted work. D-H. Park and J.C. Kamp are supported by the PRACTIS clinician scientist programme at Hannover Medical School, funded by the German Research Foundation (DGF, ME 3696/3-1). D. Berliner received honoraria for lectures/consulting from Abbott Vascular, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Edwards Lifesciences and Pfizer, and was competitively selected for “CORE100Pilot”, which is an advanced clinician scientist programme co-funded by the Else Kröner Fresenius Foundation and the Ministry for Science and Culture of the State of Lower Saxony. C. von Kaisenberg has no potential conflicts of interest to disclose. M.M. Hoeper has received fees for lectures or consultations from Acceleron, Actelion, AOP Health, Bayer, Ferrer, GossamerBio, Janssen, Keros and MSD, all unrelated to the present work. |
